Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: February 2009
-
World Research Group (WRG) will be holding its Corporate IP Counsel Summit on April 29-30, 2009 in New York, NY. The conference will provide solutions for maximizing existing IP assets, avoiding costly litigation, creating and maintaining efficient infrastructure, fully integrating IP strategy into business plans, and preparing for anticipated patent law changes. Among the presentations…
-
The Northwestern Journal of Technology & Intellectual Property (JTIP) will be holding its Fourth Annual Symposium on March 6, 2009 in Chicago, IL. The Symposium, entitled "Riding the Wave: Understanding Recent Developments in IP Law," will consist of the following sessions: • Debate on In re Bilski – a debate regarding the Federal Circuit's decision…
-
By Kevin E. Noonan — The Biotechnology Industry Organization (BIO) held one of its periodic meetings with the press today for a wide-ranging discussion of its policy goals and agendas for the new Congress and administration. A panel of BIO officials, headed by President and CEO James Greenwood, answered questions from more than a…
-
By Kevin E. Noonan — In an ironic twist, the worst economic downturn in over seventy years seems to have coincided with an economic first: according to G. Steven Burrill (at right), CEO of Burrill & Co., in 2008, the biotechnology industry became profitable for the first time in its forty-year history (see FierceBiotech…
-
By Donald Zuhn — Congressman Henry Waxman (D-CA), the Chairman of the House Committee on Energy and Commerce, addressed the Generic Pharmaceutical Association (GPhA) yesterday, telling attendees of the trade group's annual meeting in Naples, FL that "a workable scientific regulatory and legal pathway for biogenerics and biosimilar pharmaceuticals will ensure more affordable medications…
-
By Donald Zuhn — Earlier today, the Manufacturing Alliance on Patent Policy (MAPP) let us know, through its media relations firm, that "well sourced rumors" have pegged Monday, March 2nd as the day on which the first of perhaps three patent reform bills will be introduced in the 111th Congress. The 110th Congress saw…
-
By Donald Zuhn — The Federal Circuit today affirmed a decision by the District Court for the Southern District of Indiana to extend the statutory 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), thereby preventing the U.S. Food and Drug Administration from approving the Abbreviated New Drug Application (ANDA) filed by Defendant-Appellant Teva Pharmaceuticals USA,…
-
By Suresh Pillai — King Pharmaceuticals' Patents on SKELAXIN® Invalidated By District Court In the case of King Pharmaceuticals, Inc. v. Eon Labs, Inc., the U.S. District Court for the Eastern District of New York invalidated two of the King patents at issue in the case, U.S. Patent Nos. 6,407,128 and 6,683,102 as part…
-
By Donald Zuhn — It's been more than a week since the U.S. Patent and Trademark Office hosted a roundtable discussion on deferred examination. The roundtable brought together two dozen participants, representing a variety of industries and organizations, to discuss whether a deferred examination system should be implemented in the U.S. Ron Katznelson, who…
-
By Kevin E. Noonan — Like a broken clock that nonetheless tells the right time twice a day, it was inevitable that The New York Times would eventually run a story where they got it right on patenting (see "Crop Scientists Say Biotechnology Seed Companies Are Thwarting Research"). It was, of course, a story…
Patent Docs 